TFF Pharmaceuticals, Inc. (0K3.F)

0.7400 +0.0700 (+10.45%) As of 09:15AM CET. Market open.

TFF Pharmaceuticals, Inc.

1751 River Run
Suite 400
Austin, TX 76107
United States
817 438 6168
https://www.tffpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Harlan F. Weisman	CEO, Interim Pres & Vice Chairman	40k	N/A	1952
Mr. Kirk Allen Coleman	CFO, Treasurer & Sec.	378.5k	N/A	1974
Mr. Christopher Cano	COO & VP of Bus. Devel.	387.25k	N/A	1971
Dr. Anthony J. Hickey Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Dale Christensen Ph.D.	Head of Clinical Devel.	N/A	N/A	N/A
Mr. Paul F. Manley	Head of Regulatory Affairs	N/A	N/A	N/A
Dr. Zamaneh Mikhak M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Corporate Governance

TFF Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.